Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Fiscal Full Year 2025 Financial Highlights About Citius Oncology, Inc. Launched LYMPHIRâ"¢ (denileukin diftitox-cxdl), a novel IL2 receptor-directed immunotherapy, in the U.S. in December 2025 for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous Tcell lymphoma (CTCL) after at least one prior systemic therapy; Executed service agreements with the three leading U.S. pharmaceutical wholesalers to distribute LYMPHIR to healthcare organizations, including major medical centers an ...